Combination usage of adriamycin (NSC 123127) in malignant lymphomas

G. Bonadonna, M. De Lena, S. Monfardini

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The results obtained in advanced malignant lymphomas with three new drug combinations including adriamycin are reported in this paper. In patients with Hodgkin's disease, the quadruple combination of adriamycin, bleomycin, vinblastine and NSV 45388 (ABVD) in a controlled trial produced a percent of complete remission and a median duration of response comparable to those obtained with mechlorethamine, vincristine, (oncovin) prednisone and procarbazine (MOPP). Similar results were observed in the group of patients with nonHodgkin's lymphomas where adriamycin, bleomycin, and prednisone (ABP) were randomly tested against cyclophosphamide, vincristine, and prednisone (CVP). Initial evidence shows a lack of cross resistance between ABVD and MOPP as well as between ABP and CVP. These data favor the design of new combinations and new approaches for the best management of patients with advanced malignant lymphomas. Combinations that include adriamycin and bleomycin may, however, produce severe toxicity (cardiomyopathy, lung fibrosis) when these drugs are used as longterm therapy.

Original languageEnglish
Title of host publicationCANCER CHEMOTHER.REP.
Pages381-388
Number of pages8
Volume6
Edition2
Publication statusPublished - 1975

Fingerprint

Prednisone
Doxorubicin
Bleomycin
Vincristine
Lymphoma
Cyclophosphamide
Procarbazine
Mechlorethamine
Vinblastine
Drug Combinations
Hodgkin Disease
Cardiomyopathies
Non-Hodgkin's Lymphoma
Fibrosis
Lung
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bonadonna, G., De Lena, M., & Monfardini, S. (1975). Combination usage of adriamycin (NSC 123127) in malignant lymphomas. In CANCER CHEMOTHER.REP. (2 ed., Vol. 6, pp. 381-388)

Combination usage of adriamycin (NSC 123127) in malignant lymphomas. / Bonadonna, G.; De Lena, M.; Monfardini, S.

CANCER CHEMOTHER.REP.. Vol. 6 2. ed. 1975. p. 381-388.

Research output: Chapter in Book/Report/Conference proceedingChapter

Bonadonna, G, De Lena, M & Monfardini, S 1975, Combination usage of adriamycin (NSC 123127) in malignant lymphomas. in CANCER CHEMOTHER.REP.. 2 edn, vol. 6, pp. 381-388.
Bonadonna G, De Lena M, Monfardini S. Combination usage of adriamycin (NSC 123127) in malignant lymphomas. In CANCER CHEMOTHER.REP.. 2 ed. Vol. 6. 1975. p. 381-388
Bonadonna, G. ; De Lena, M. ; Monfardini, S. / Combination usage of adriamycin (NSC 123127) in malignant lymphomas. CANCER CHEMOTHER.REP.. Vol. 6 2. ed. 1975. pp. 381-388
@inbook{cdf2dd5569654e658bb3fa4ef5d6b62a,
title = "Combination usage of adriamycin (NSC 123127) in malignant lymphomas",
abstract = "The results obtained in advanced malignant lymphomas with three new drug combinations including adriamycin are reported in this paper. In patients with Hodgkin's disease, the quadruple combination of adriamycin, bleomycin, vinblastine and NSV 45388 (ABVD) in a controlled trial produced a percent of complete remission and a median duration of response comparable to those obtained with mechlorethamine, vincristine, (oncovin) prednisone and procarbazine (MOPP). Similar results were observed in the group of patients with nonHodgkin's lymphomas where adriamycin, bleomycin, and prednisone (ABP) were randomly tested against cyclophosphamide, vincristine, and prednisone (CVP). Initial evidence shows a lack of cross resistance between ABVD and MOPP as well as between ABP and CVP. These data favor the design of new combinations and new approaches for the best management of patients with advanced malignant lymphomas. Combinations that include adriamycin and bleomycin may, however, produce severe toxicity (cardiomyopathy, lung fibrosis) when these drugs are used as longterm therapy.",
author = "G. Bonadonna and {De Lena}, M. and S. Monfardini",
year = "1975",
language = "English",
volume = "6",
pages = "381--388",
booktitle = "CANCER CHEMOTHER.REP.",
edition = "2",

}

TY - CHAP

T1 - Combination usage of adriamycin (NSC 123127) in malignant lymphomas

AU - Bonadonna, G.

AU - De Lena, M.

AU - Monfardini, S.

PY - 1975

Y1 - 1975

N2 - The results obtained in advanced malignant lymphomas with three new drug combinations including adriamycin are reported in this paper. In patients with Hodgkin's disease, the quadruple combination of adriamycin, bleomycin, vinblastine and NSV 45388 (ABVD) in a controlled trial produced a percent of complete remission and a median duration of response comparable to those obtained with mechlorethamine, vincristine, (oncovin) prednisone and procarbazine (MOPP). Similar results were observed in the group of patients with nonHodgkin's lymphomas where adriamycin, bleomycin, and prednisone (ABP) were randomly tested against cyclophosphamide, vincristine, and prednisone (CVP). Initial evidence shows a lack of cross resistance between ABVD and MOPP as well as between ABP and CVP. These data favor the design of new combinations and new approaches for the best management of patients with advanced malignant lymphomas. Combinations that include adriamycin and bleomycin may, however, produce severe toxicity (cardiomyopathy, lung fibrosis) when these drugs are used as longterm therapy.

AB - The results obtained in advanced malignant lymphomas with three new drug combinations including adriamycin are reported in this paper. In patients with Hodgkin's disease, the quadruple combination of adriamycin, bleomycin, vinblastine and NSV 45388 (ABVD) in a controlled trial produced a percent of complete remission and a median duration of response comparable to those obtained with mechlorethamine, vincristine, (oncovin) prednisone and procarbazine (MOPP). Similar results were observed in the group of patients with nonHodgkin's lymphomas where adriamycin, bleomycin, and prednisone (ABP) were randomly tested against cyclophosphamide, vincristine, and prednisone (CVP). Initial evidence shows a lack of cross resistance between ABVD and MOPP as well as between ABP and CVP. These data favor the design of new combinations and new approaches for the best management of patients with advanced malignant lymphomas. Combinations that include adriamycin and bleomycin may, however, produce severe toxicity (cardiomyopathy, lung fibrosis) when these drugs are used as longterm therapy.

UR - http://www.scopus.com/inward/record.url?scp=0016718763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016718763&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:0016718763

VL - 6

SP - 381

EP - 388

BT - CANCER CHEMOTHER.REP.

ER -